Immunosignaturing can detect products from molecular markers in brain cancer.
Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifi...
Guardado en:
Autores principales: | , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a08d902f933840fc864600a5e992ab5b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:a08d902f933840fc864600a5e992ab5b |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:a08d902f933840fc864600a5e992ab5b2021-11-18T07:12:26ZImmunosignaturing can detect products from molecular markers in brain cancer.1932-620310.1371/journal.pone.0040201https://doaj.org/article/a08d902f933840fc864600a5e992ab5b2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22815729/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors. Blood samples from patients undergoing craniotomies for therapeutically naïve brain tumors with diagnoses of astrocytoma (23 samples), Glioblastoma multiforme (22 samples), mixed oligodendroglioma/astrocytoma (16 samples), oligodendroglioma (18 samples), and 34 otherwise healthy controls were tested by immunosignature. Because samples were taken prior to adjuvant therapy, they are unlikely to be perturbed by non-cancer related affects. The immunosignaturing platform distinguished not only brain cancer from controls, but also pathologically important features about the tumor including type, grade, and the presence or absence of O(6)-methyl-guanine-DNA methyltransferase methylation promoter (MGMT), an important biomarker that predicts response to temozolomide in Glioblastoma multiformae patients.Alexa K HughesZbigniew CichaczAdrienne ScheckStephen W CoonsStephen Albert JohnstonPhillip StaffordPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 7, p e40201 (2012) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Alexa K Hughes Zbigniew Cichacz Adrienne Scheck Stephen W Coons Stephen Albert Johnston Phillip Stafford Immunosignaturing can detect products from molecular markers in brain cancer. |
description |
Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors. Blood samples from patients undergoing craniotomies for therapeutically naïve brain tumors with diagnoses of astrocytoma (23 samples), Glioblastoma multiforme (22 samples), mixed oligodendroglioma/astrocytoma (16 samples), oligodendroglioma (18 samples), and 34 otherwise healthy controls were tested by immunosignature. Because samples were taken prior to adjuvant therapy, they are unlikely to be perturbed by non-cancer related affects. The immunosignaturing platform distinguished not only brain cancer from controls, but also pathologically important features about the tumor including type, grade, and the presence or absence of O(6)-methyl-guanine-DNA methyltransferase methylation promoter (MGMT), an important biomarker that predicts response to temozolomide in Glioblastoma multiformae patients. |
format |
article |
author |
Alexa K Hughes Zbigniew Cichacz Adrienne Scheck Stephen W Coons Stephen Albert Johnston Phillip Stafford |
author_facet |
Alexa K Hughes Zbigniew Cichacz Adrienne Scheck Stephen W Coons Stephen Albert Johnston Phillip Stafford |
author_sort |
Alexa K Hughes |
title |
Immunosignaturing can detect products from molecular markers in brain cancer. |
title_short |
Immunosignaturing can detect products from molecular markers in brain cancer. |
title_full |
Immunosignaturing can detect products from molecular markers in brain cancer. |
title_fullStr |
Immunosignaturing can detect products from molecular markers in brain cancer. |
title_full_unstemmed |
Immunosignaturing can detect products from molecular markers in brain cancer. |
title_sort |
immunosignaturing can detect products from molecular markers in brain cancer. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2012 |
url |
https://doaj.org/article/a08d902f933840fc864600a5e992ab5b |
work_keys_str_mv |
AT alexakhughes immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer AT zbigniewcichacz immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer AT adriennescheck immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer AT stephenwcoons immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer AT stephenalbertjohnston immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer AT phillipstafford immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer |
_version_ |
1718423806254514176 |